Samsung Semiconductor Europe Completes EMEA Headquarters Relocation to New Munich Office
18.11.2020 12:00:00 EET | Business Wire | Press release
Samsung Semiconductor Europe, a wholly owned subsidiary of Samsung Electronics. Co., Ltd. has announced today that the relocation of its EMEA headquarters from the Frankfurt region to Munich, a leading high-tech hub in Germany, is now completed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005044/en/
Samsung Semiconductor Europe at Bavaria Towers, Munich (Photo: Business Wire)
Aiming to be on the doorstep of many key customers and partners with whom the company is driving digital transformation across industries, Samsung Semiconductor Europe started moving into the new Bavaria Towers in early 2020. Consolidating the already existing Ismaning office along the way, the relocation process was finally completed by closing the previous location near Frankfurt by end of September.
“Faster response times to our customers and attracting the best talent in this technology hub are key for Samsung Semiconductor Europe to remain a leading solution provider for the next few decades,” said Dermot Ryan, managing director at Samsung Semiconductor Europe. “By embracing future trends like artificial intelligence (AI), 5G, internet of things (IoT), big data, cloud computing, automotive and more, we work at the chip and basic software level, not only to make our own devices more intelligent, but also to enable entire industries to become smarter. The move to Munich marks a new era for Samsung Semiconductor Europe as we embark upon a new age of innovation, cooperation and trust together with our employees, customers and partners.”
“As the state capital of Bavaria, Munich is not only an international and culturally diverse city in a beautiful environment, it is also Germany‘s foremost tech hub and one of the leading cities in digital transformation,“ says Clemens Baumgärtner, head of the Department of Labor and Economic Development, City of Munich. “Munich offers excellent infrastructure and a vibrant ecosystem of companies, universities, start-ups and professional networks to companies in the areas of high-tech, IoT and services. We are more than happy to welcome Samsung Semiconductor Europe to shape the future of our region together.”
Munich has not only a leading position within Germany’s ICT sector, with 119.000 employees and 11.300 companies in and around the area according to the Bavarian Statistical Office, it also ranks high within European ICT poles of excellence, according to a study of the European Commission.
At Bavaria Towers, Samsung Semiconductor Europe employs around 170 staff from a large variety of countries in sales and marketing for Samsung Electronics’ component business units in Europe, the Middle East and Africa along with its sales offices in Finland, France, Turkey and the UK. From a technology point of view, Samsung Semiconductor Europe provides component solutions featuring industry-leading technologies in the areas of memory, system LSI, foundry, LED and display, often setting a new standard in the industry.
The company also offers a dynamic work culture in an exciting and inspiring atmosphere. As employees’ health and safety are one of its top priorities, the company provides a variety of employee benefits for improved work-life balance and thrives on a diverse and empowering work environment.
To learn more about Samsung Semiconductor Europe, please visit https://www.linkedin.com/showcase/samsung-semi-europe/
###
About Samsung Semiconductor Europe GmbH
Samsung Semiconductor Europe, a wholly owned subsidiary of Samsung Electronics Co. Ltd., is headquartered in Munich, Germany and operates offices in Europe, Middle East and Africa (EMEA). Samsung Semiconductor's European base handles the marketing and sales of Samsung Electronics' component business units including Memory, System LSI, Foundry, LED and Display in EMEA for various applications including servers, data centres, mobile, industrial/automotive, IoT and more. For more information, please visit www.samsung.com/semiconductor.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005044/en/
Contact information
Ujeong Jahnke
Samsung Semiconductor Europe GmbH
Tel. +49(0)89-45578-1000
Email: ujeong.j@samsung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom